The UK start-up Pneumagen Ltd has been working on a novel way of blocking the entry of pathogens including influenza and coronaviruses into human cells, and expects to start clinical studies with its lead product, Neumifil, a multivalent protein, in 2021.
The technology under development by Pneumagen has its origins in research conducted more than 10 years ago at St Andrews...